In the media
November 18, 2021
Sanofi signs a $270M strategic partnership with Owkin to research new treatments across four cancers
About Owkin
Owkin is an agentic AI company on a mission to explore complex biology to speed up and scale research for the creation of new treatments and diagnostics for patients. Owkin K, our AI co-pilot combines unparalleled access to multimodal data, cutting-edge AI to quantify biology and pioneering agentic AI to achieve Biological Artificial Superintelligence in the future.